AstraZeneca and Daiichi Sankyo plan to seek approval for their breast cancer treatment datopotamab deruxtecan (Dato-DXd) following a clinical trial that revealed improved patient outcomes. The study included over 700 participants with inoperable or metastatic HR-positive, HER2-low, or negative breast cancer, and it observed that Dato-DXd improved progression-free survival compared to chemotherapy. However, the overall survival (OS) data remains inconclusive. The public announcements from the companies provided hopeful yet varying perspectives regarding the OS results, inciting conjecture among stakeholders and market analysts. Additional information on the experiment’s results will be presented at a forthcoming medical event. Following the disclosure of preliminary results, AstraZeneca’s stocks climbed 2.7%.
To read more, click here.
[Source: Fierce Biotech, September 22nd, 2023]